Mersana Therapeutics, Inc. (NASDAQ:MRSN) has a beta value of 2.43 and has seen 749,280 shares traded in the last trading session. The company, currently valued at $1.6 Billion, closed the last trade at $23.35 per share which meant it lost -$0.12 on the day or -0.51% during that session. The MRSN stock price is -14.09% off its 52-week high price of $26.64 and 86.47% above the 52-week low of $3.16. If we look at the company’s 10-day average daily trading volume, we find that it stood at 840.61 Million shares traded. The 3-month trading volume is 961.59 Million shares.
The consensus among analysts is that Mersana Therapeutics, Inc. (MRSN) is an Overweight stock at the moment, with a recommendation rating of 1.5. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. 1 out of 6 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.32.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) trade information
Despite being -0.51% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Nov 17 when the MRSN stock price touched $24.23- or saw a rise of 3.63%. Year-to-date, Mersana Therapeutics, Inc. shares have moved 307.5%, while the 5-day performance has seen it change 3.59%. Over the past 30 days, the shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) have changed 35.05%. Short interest in the company has seen 6.53 Million shares shorted with days to cover at 0.01.
Wall Street analysts have a consensus price target for the stock at $27.4, which means that the shares’ value could jump 17.34% from current levels. The projected low price target is $20 while the price target rests at a high of $32. In that case, then, we find that the current price level is +37.04% off the targeted high while a plunge would see the stock lose -14.35% from current levels.
Mersana Therapeutics, Inc. (MRSN) estimates and forecasts
Figures show that Mersana Therapeutics, Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained +117.01% over the past 6 months, with this year growth rate of 104.62%, compared to 14.5% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 5.9% and 11.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be -97.6%.
5 analysts offering their estimates for the company have set an average revenue estimate of $200Million for the current quarter. 3 have an estimated revenue figure of $530Million for the next quarter concluding in March 01, 2021. Year-ago sales stood $42Million and $11Million respectively for this quarter and the next, and analysts expect sales will grow by 376.2% for the current quarter and 4718.2% for the next.
Earnings growth for 2020 is a modest +76.8%.
Mersana Therapeutics, Inc. (NASDAQ:MRSN)’s Major holders
Insiders own 1.14% of the company shares, while shares held by institutions stand at 100.95% with a share float percentage of 102.11%. Investors are also buoyed by the number of investors in a company, with Mersana Therapeutics, Inc. having a total of 190 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 7.25 Million shares worth more than $135.03 Million. As of September 29, 2020, Blackrock Inc. held 10.59% of shares outstanding.
The other major institutional holder is Avoro Capital Advisors LLC, with the holding of over 6.8 Million shares as of September 29, 2020. The firm’s total holdings are worth over $126.62 Million and represent 9.93% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and BlackRock Health Sciences Trust II. As of October 30, 2020, the former fund manager holds about 2.9% shares in the company for having 1983259 shares of worth $35.74 Million while later fund manager owns 1.75 Million shares of worth $41Million as of June 29, 2020, which makes it owner of about 2.56% of company’s outstanding stock.